Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$143.00
▼ $0.70 (-0.5%)
Market data updated: 09/19 02:41 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$9.25B
Day Range
$140.44 - $144.58
52-Week Range
$61.95 - $160.81
Beta
—
Next Earnings
04.11.2026
Support
$125.32
Resistance
$160.81
PTGX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+130.1% (1Y)
Strengths: 5/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Calmar Ratio (return vs. drawdown)
Calmar: 3.19 (3y annualized return 100.8% / max drawdown 31.6%)
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: $22.51 vs. price $143.00 (-84.3%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $143.00
Evidence: Euphoria score crossed 55 (now 55)
What happened after
Still awaiting outcome
4d ago · $147.78
Evidence: Euphoria score crossed 55 (now 56)
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
26
Quality
42
Value
38
Momentum
39
Risk
64
Sentiment
86
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Protagonist Therapeutics (PTGX) has centered on its financial turnaround and strategic milestones. The company reported a $162.8 million profit in Q2 2026, reversing a prior loss, as two drugs neared blockbuster potential. A $275 million payout—including a $200 million opt-out fee and $75 million milestone—followed the FDA approval of its drug MIMRYLO (rusfertide). Additionally, Protagonist announced a $300 million share repurchase program and CEO participation in investment bank conferences, while analysts debated whether its stock remains overvalued despite strong recent performance.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Protagonist Therapeutics, Inc.. News trend score: 86. Reason: 8 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
47
🎯 Conviction (vs. Emotion)
19
Psychology
64
Fundamentals
30
Technical
39
Valuation
38
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+27%
Market Narrative
68
Fundamental Reality
19
Narrative Gap
+49
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant confirmation bias reflects a stubborn narrative gap (+40) where fundamentals (revenue decline, margin compression) contradict investor optimism. Euphoria and overconfidence persist due to extreme valuation (+548% above DCF), despite weak momentum. The key question is whether traders will pivot from selective data (ignoring fundamentals) or acknowledge the disconnect. Low FOMO/Panic scores suggest no panic-driven selling or herd behavior, but elevated volume hints at cautious positioning. The open question: Will the narrative gap widen further, or will fundamentals force a re-evaluation?
Updated: 09/09/2026, 07:12 AM
What could change this?
👥 What the crowd believes
"$275M payments triggered by MIMRYLO approval (articles 4, 5, 11)"
"swung to $162.8M profit in Q2 2026 (articles 2, 3)"
"Barclays raises price target to $180 (article 10) / Overweight rating (article 10)"
"$300M share repurchase program authorized (article 1)"
🧠 Market Brain events driving this
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 4/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between cyclical optimism and deep structural concerns. Walter Bagehot’s near-perfect score highlights liquidity resilience, suggesting the company could weather financial stress, while Samuel Nelson’s favorable cycle positioning implies it may be undervalued relative to its market cycle. However, the majority of methodologies—from Graham’s defensive criteria to Fisher’s quality standards—reject the stock outright, flagging weak fundamentals, speculative momentum, or late-cycle risks. Even the efficient-market approach dismisses it as unworthy of active selection, while volatility-focused thinkers like Morgan Housel and Thorstein Veblen warn of unsustainable trends or emotional crowding. The divide underscores whether PTGX is a temporary cyclical play or a speculative bubble, with only a handful of investors seeing any merit in its current state.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 86
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 44
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 42
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 34
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 27
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 17
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 8
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 7
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 4
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 6 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-343.6%
Net Margin
-282.8%
EBITDA Margin
-340.9%
ROE
-21.2%
ROA
-19.5%
ROIC
—
EPS
-$2.05
Cash
$128.39M
Total Debt
—
Current Ratio
12.71
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$143.00
Estimated Fair Value (DCF)
$22.51
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-84.3%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $70.10M | $64.31M |
| 2 | 19.4% | $83.68M | $70.43M |
| 3 | 13.8% | $95.19M | $73.50M |
| 4 | 8.1% | $102.92M | $72.91M |
| 5 | 2.5% | $105.50M | $68.57M |
Base FCF (last actual year)
$56.08M
Terminal Value
$1.66B
Present Value of Terminal Value
$1.08B
Enterprise Value
$1.43B
Net Debt
$0
Equity Value
$1.43B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$9.67
Tangible Book Value per Share (Tangible NAV)
$9.67
Sentiment based on basic keywords (not AI) — 8 positive, 10 neutral, 2 negative out of the last 20 articles.
Yahoo · 18.9.2026
ChartMill · 15.9.2026
MT Newswires · 11.9.2026
SeekingAlpha · 9.9.2026
ACCESS Newswire · 8.9.2026
Yahoo · 8.9.2026
Benzinga · 8.9.2026
Yahoo · 6.9.2026
Insider Monkey · 6.9.2026
Yahoo · 4.9.2026
Insider Monkey · 4.9.2026
Yahoo · 2.9.2026
ACCESS Newswire · 2.9.2026
Yahoo · 1.9.2026
Simply Wall St. · 1.9.2026
Benzinga · 1.9.2026
Yahoo · 1.9.2026
Simply Wall St. · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 1.9.2026
Protagonist Therapeutics, Inc. (PTGX) currently has a StockIQ AI score of 41/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PTGX currently scores 41/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PTGX's estimated fair value is $22.51, which is 84.3% below the current price of $143.00. This is one valuation model among several signals in the fair-value category, not a price target.
PTGX's technical score is 39/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Calmar: 3.19 (3y annualized return 100.8% / max drawdown 31.6%); Current ratio: 12.71; Price is above the 200-day average.
Based on the real signals StockIQ computed: Estimated fair value: $22.51 vs. price $143.00 (-84.3%); Operating margin: -343.6% (negative); Net margin: -282.8% (negative).
StockIQ has no recorded dividend payment history for PTGX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| PATEL DINESH V PH D | Gift | 3.9.2026 | 510 | -510 | — |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 11.8.2026 | 125,000 | -34,239 | — |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 11.8.2026 | 557,717 | +34,239 | $21.58 |
| PATEL DINESH V PH D | Open Market Sale | 11.8.2026 | 523,478 | -34,239 | $148.52 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 11.8.2026 | 34,239 | -34,239 | — |
| PATEL DINESH V PH D | Open Market Sale | 11.8.2026 | 34,239 | -34,239 | $148.52 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 11.8.2026 | 34,239 | +34,239 | $21.58 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 10.8.2026 | 589,239 | +65,761 | $21.58 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 10.8.2026 | 159,239 | -65,761 | — |
| PATEL DINESH V PH D | Open Market Sale | 10.8.2026 | 523,478 | -65,761 | $149.11 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 10.8.2026 | 65,761 | -65,761 | — |
| PATEL DINESH V PH D | Open Market Sale | 10.8.2026 | 65,761 | -65,761 | $149.11 |
| PATEL DINESH V PH D | Exercise of Derivative Securities | 10.8.2026 | 65,761 | +65,761 | $21.58 |
| Waddill William D. | Exercise of Derivative Securities | 23.6.2026 | 9,000 | +9,000 | $16.54 |
| Waddill William D. | Exercise of Derivative Securities | 23.6.2026 | 9,000 | -9,000 | — |
| Waddill William D. | Open Market Sale | 23.6.2026 | 9,000 | -9,000 | $117.94 |
| Waddill William D. | Exercise of Derivative Securities | 23.6.2026 | 16,825 | +9,000 | $16.54 |
| Waddill William D. | Open Market Sale | 23.6.2026 | 7,825 | -9,000 | $117.94 |
| Waddill William D. | Exercise of Derivative Securities | 23.6.2026 | 0 | -9,000 | — |
| Waddill William D. | Exercise of Derivative Securities | 10.6.2026 | 3,000 | -3,000 | — |
| Waddill William D. | Exercise of Derivative Securities | 10.6.2026 | 6,000 | -6,000 | — |
| Waddill William D. | Exercise of Derivative Securities | 10.6.2026 | 3,000 | +3,000 | $11.80 |
| Waddill William D. | Exercise of Derivative Securities | 10.6.2026 | 6,000 | +6,000 | $16.54 |
| Waddill William D. | Open Market Sale | 10.6.2026 | 9,000 | -9,000 | $107.68 |
| Waddill William D. | Exercise of Derivative Securities | 10.6.2026 | 10,825 | +3,000 | $11.80 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,712,543 shares short as of 2026-08-31 · vs. 7,543,109 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
73.3% of trading volume this week was short selling, vs. 78.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology